Calithera Drops Development Of Lead Candidate Telaglenastat

Interim Phase II Lung Cancer Data Underwhelming

08 Nov 2021

• By Ayisha Sharma

Calithera’s most advanced oncological asset, telaglenastat, has failed in yet another indication, prompting the company to fall back on candidates in-licensed from Takeda just last month.

Telaglenastat Was First Glutaminase Inhibitor In Clinic • Source: Alamy

Calithera Biosciences, Inc. has terminated development of its lead asset, telaglenastat, based on interim Phase II study data in lung cancer, forcing the company to re-shift its focus to two recently acquired oncology candidates.

The California-based biotech has no plans to develop the glutaminase inhibitor any further, and hopes instead to leverage its expertise...